Trial · NCT07222761
Registered outcomes44
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 40 of 44
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Time to VGPR IMWG response category | Up to 5 years | Part 2 |
| Secondary | Time to CR IMWG response category | Up to 5 years | Part 2 |
| Secondary | Time to stringent Complete Response (sCR) IMWG response category | Up to 5 years | Part 2 |
| Secondary | Sustained MRD-negative CR | Up to 5 years | Part 2 |
| Secondary | Duration of MRD-negative CR | Up to 5 years | Part 2 |
| Secondary | Occurrence of TEAEs | Up to 5 years | Part 2 |
| Secondary | Severity of TEAEs | Up to 5 years | Part 2 |
| Secondary | Occurrence of AESIs | Up to 5 years | Part 2 |
| Secondary | Severity of AESIs | Up to 5 years | Part 2 |
| Secondary | Occurrence of SAEs | Up to 5 years | Part 2 |
| Secondary | Severity of SAEs | Up to 5 years | Part 2 |
| Secondary | Concentrations of linvoseltamab in serum over time | Up to 5 years | Part 2 |
| Secondary | Incidence of Antidrug Antibodies (ADAs) to linvoseltamab | Up to 5 years | Part 2 |
| Secondary | Magnitude of ADAs to linvoseltamab | Up to 5 years | Part 2 |
| Secondary | Concentrations total soluble B-cell Maturation Antigen (sBCMA) in serum over time | Up to 5 years | Part 2 |
| Secondary | Change from baseline in Global Health Status (GHS)/Quality of Life (QoL), per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) | Up to 5 years | Part 2 The EORTC QLQ-C30 is a 30-item validated questionnaire developed to measure patient-reported QoL using 1 GHS/QoL scale, 5 functioning scales (physical, role, emotional, cognitive and social) and 9 symptom scales / items (fatigue, nausea/vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea and financial difficulties) among patients with cancer. Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much." |
| Secondary | Change from baseline in Physical Functioning (PF), per EORTC QLQ-C30 | Up to 5 years | Part 2 |
| Secondary | Change from baseline in Role Functioning (RF), per EORTC QLQ-C30 | Up to 5 years | Part 2 |
| Secondary | Change from baseline in pain, per EORTC QLQ-C30 | Up to 5 years | Part 2 |
| Secondary | Change from baseline in fatigue, per EORTC QLQ-C30 | Up to 5 years | Part 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07222761/registered?page=2